Skip to main content
SpringerPlus

Table 2 First-line chemotherapy regimens administered in the two groups of patients

From: Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis

Group A

N. patients

Group B

N. patients

PELF

138 (64 %)

CDDP + 5-FU

86 (41 %)

ECF

12 (5.5 %)

FOLFOX

43 (21 %)

CDDP + 5-FU + MMC

50 (23 %)

5-FU + MMC

56 (27 %)

TCF

12 (5.5 %)

FOLFIRI

14 (6.7 %)

FAM

4 (2 %)

CDDP + docetaxel

9 (4 %)

  

IROX

1 (0.3 %)

  1. PELF (cisplatin, epirubicin, 5-FU and leucovorin), ECF (epirubicin, cisplatin and 5-FU), TCF (docetaxel, cisplatin, 5-FU), MMC (mytomicin C), FAM (5-FU, adriamycin, cyclofosfamid) CDDP (cisplatin), FOLFIRI (5-FU, leucovorin, irinotecan, irinotecan), IROX (irinotecan, oxaliplatin)
Back to article page